Sep 2026· Cancer Letters· pp.
218850
· 0 citations· 60 references
Medicine
TL;DR
It is found that PLK4 was up-regulated in DLBCL, and its silencing significantly inhibited tumor growth, and the combination of si-PLK4 and VCR exerted stronger anti-tumor effects than either treatment alone, which was mediated by activating cGAS-STING pathway.
Abstract
Despite the emergence of immunotherapies, the treatment of diffuse large B-cell lymphoma (DLBCL) remains challenging. This is mainly attributed to the immunosuppressive properties of the tumor microenvironment (TME), which limit the achievement of durable therapeutic responses. High expression of Polo-like kinase 4 (PLK4), a mitotic kinase, is associated with significantly poorer survival outcomes in DLBCL patients receiving CHOP-based chemotherapy. Moreover, the combination of mitotic kinase inhibitors and the microtubules-targeting agent vincristine (VCR) exhibit synergistic anti-tumor effects in B-cell lymphoma mouse models. In this study, we found that PLK4 was up-regulated in DLBCL, and its silencing significantly inhibited tumor growth. Furthermore, the combination of si-PLK4 and VCR exerted stronger anti-tumor effects than either treatment alone, which was mediated by activating cGAS-STING pathway. Based on these findings, we developed a nanomedicine-based therapeutic strategy for DLBCL using zeolite imidazole framework (ZIF)-90 as carrier for co-delivery of VCR and si-PLK4. To enhance targeting specificity toward CD20+ lymphoma cells, rituximab (RTX) was conjugated onto the nanomedicine, named VCR/siPLK4@ZIF-90-RTX. The VCR/siPLK4@ZIF-90-RTX showed minimal premature release of VCR and siPLK4, with a pH-responsive release profile. Compared with the combination of VCR and RTX, VCR/siPLK4@ZIF-90-RTX showed enhanced anti-tumor effects in vitro, and exhibited high biocompatibility and low toxic side effects in vivo. Moreover, VCR/siPLK4@ZIF-90-RTX could promote the maturation of dendritic cells and subsequent tumor infiltration of CD8+ T and CD4+ T cells by activating cGAS-STING pathway. Collectively, this work provides a potential synergistic chemo-immunotherapeutic strategy that effectively remodels the immunosuppressive TME and improves therapeutic efficacy.
A review elucidates the molecular insights into the detailed mechanisms of chemoresistance in DLBCL and the developments in nanomedicine as a potential model for precision lymphoma therapy.
Dan-Yang Li, Xiao-Yan Ke, Kai Hu· Biochimica et biophysica act...· 0 citations
Work using metastatic mouse models shows that the antitumor response is multifactorial, comprising downregulation of myeloid-mediated CD8+ T-cell suppression along with increased B-cell and plasma cell activation, antibody production, and tertiary lymphoid structure (TLS) maturation.
Y. Senent, R. Manguso· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PCAD) remains one of the deadliest cancers with minimal treatment options, highlighting the need for more effective immunotherapeutic strategies capable of overcoming its highly immunosuppressive tumor microenvironment. Tumor penetrating peptides such as iRGD enhance the delivery and...
M. Harari, In Hwan Park, Shawn A. Abeynaike et al.· Cancer Research· 0 citations
Vaccination with enfortumab vedotin-treated tumor cells results in protection against tumor rechallenge in mice, consistent with antitumor immunity, and MMAE-mediated ICD induction modulates the tumor microenvironment in a complementary manner to immune checkpoint inhibition.
Devra J. Olson, Bernard A. Liu, Patrick Younan et al.· Cell Reports Medicine· 0 citations
It is demonstrated that γδ T cells are effective at tarlatamab (delta-like ligand 3 [DLL3]-CD3 bispecific T cell engager [BiTE])-redirected SCLC killing and that zoledronate can sensitize SCLC cells to γδ T cell-mediated killing.
Jin Ng, Yue You, Tina Zhang et al.· Cancer Cell· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.